Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 5/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19150035 | 0.91 | KDM1A (0.33) | MTNR1AMTNR1BCNR2TSHRMEN1 | |
| SCHEMBL17747078 | 0.86 | NAMPT (0.35) | MTNR1AMTNR1BL3MBTL1TSHRMEN1 | |
| SCHEMBL26758488 | 0.86 | TSHR (0.42) | MTNR1AMTNR1BCNR2L3MBTL1TSHR | |
| SCHEMBL2742841 | 0.86 | TSHR (0.42) | MTNR1AMTNR1BCNR2L3MBTL1TSHR | |
| SCHEMBL29263611 | 0.84 | MTNR1A (0.33) | MTNR1AMTNR1BCNR2L3MBTL1TSHR | |
| SCHEMBL31296167 | 0.84 | MTNR1A (0.33) | MTNR1AMTNR1BCNR2L3MBTL1TSHR | |
| SCHEMBL17766460 | 0.84 | MTNR1A (0.33) | MTNR1AMTNR1BCNR2L3MBTL1TSHR | |
| SCHEMBL16441216 | 0.84 | CNR2 (0.39) | MTNR1AMTNR1BCNR2L3MBTL1TSHR | |
| SCHEMBL19149837 | 0.83 | TSHR (0.37) | MTNR1AMTNR1BCNR2L3MBTL1TSHR | |
| SCHEMBL17067939 | 0.81 | SMN1; SMN2 (0.38) | MTNR1AMTNR1BCNR2L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200093816-A1 | SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTICS AGENTS | SERINA THERAPEUTICS (AL), INC. | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093816-A1 | SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTICS AGENTS | CD44, CD47, LNPEP | MTNR1A 2591/4885MTNR1B 2899/4885CNR2 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.